In the following video, Motley Fool health care analyst Brenton Flynn discusses Bausch & Lomb and the scuttlebutt surrounding a potential acquirer. He talks about Abbott Labs (ABT 0.41%), Johnson & Johnson (JNJ +1.26%), Sanofi (SNY 1.40%), Pfizer (PFE 0.19%), and Merck (MRK +5.63%), and just how realistic this purchase would be for each. He also gives his bet on which company, in the end, may be the buyer.